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The exact mechanisms by which treatment with hyperbaric oxygen (HBOT) exerts its beneficial effects on recovery after brain
injury are still unrevealed. Therefore, in this study we investigated the influence of repetitive HBOT on the reactive astrogliosis
and expression of mediators of inflammation after cortical stab injury (CSI). CSI was performed on male Wistar rats, divided into
control, sham, and lesioned groups with appropriate HBO. The HBOT protocol was as follows: 10 minutes of slow compression,
2.5 atmospheres absolute (ATA) for 60 minutes, and 10 minutes of slow decompression, once a day for 10 consecutive days. Data
obtained using real-time polymerase chain reaction, Western blot, and immunohistochemical and immunofluorescence analyses
revealed that repetitive HBOT applied after the CSI attenuates reactive astrogliosis and glial scarring, and reduces expression of
GFAP (glial fibrillary acidic protein), vimentin, and ICAM-1 (intercellular adhesion molecule-1) both at gene and tissue levels.
In addition, HBOT prevents expression of CD40 and its ligand CD40L on microglia, neutrophils, cortical neurons, and reactive
astrocytes. Accordingly, repetitive HBOT, by prevention of glial scarring and limiting of expression of inflammatory mediators,
supports formation of more permissive environment for repair and regeneration.
1. Introduction
Increased inflammatory reaction is elicited after traumatic
brain injury (TBI) in areas proximal and distal to the locus
of primary insult [1–3]. An invasion of macrophages and
neutrophils into the impact area is triggered, and they initiate
much of the inflammation and swelling in damaged areas
that can directly affect the outcome after TBI [4, 5]. It
is well documented that the basic mechanisms underlying
neuroinflammatory cascade involves activation and ligation
of CD40 ligand (CD40L, also termed CD154, or GP39) and
its counter receptor CD40 [6]. On the surface of vascu-
lar endothelial cells, CD40/CD40L ligation upregulates pro-
duction of ICAM-1 (CD54), an adhesion molecule that
is important for transendothelial migration of neutrophils
and propagation of inflammation [7, 8]. Considering that
CD40/CD40L dyad fosters neuroinflammation, some studies
suggest that CD40/CD40L interaction may be involved in
modulating the outcome from injuries of the brain [9–
11]. Strategies aimed at suppressing CD40/CD40L/ICAM-
1 expression, therefore, may attenuate inflammation and
neuronal damage after TBI, whichwill ultimately be of benefit
in recovery [12].
Another obstacle for a successful recovery after TBI is
the existence of nonpermissive glial scar, which prevents ax-
onal sprouting and the establishment of new neural circuits
but also isolates intact central nervous system (CNS) tissue
from secondary lesions [13, 14]. The glial scar consists
mainly of reactive astrocytes, which upon TBI undergo
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reactive astrogliosis involving cell proliferation, hypertrophy,
and an enhancement of immune-modulating capacities [9,
15]. Therefore, downregulation of reactive astrogliosis will
produce permissive environment for neurite outgrowth and
formation of new synaptic connections and decrease inflam-
mation.
Posttraumatic imbalance between cerebral oxygen deliv-
ery and cerebral oxygen consumption is also one of the
consequences of TBI [16]. Among different therapies, several
animal and clinical studies have demonstrated promising
effects of hyperbaric oxygenation (HBO) after various types
of brain injuries [17–19]. Over the years treatment with
hyperbaric oxygen (HBOT) has become the primary therapy
for a variety of clinical conditions [20], including dose-
dependent effects on inflammation, angiogenesis, blood-
brain barrier (BBB) integrity, and wound healing [17, 21–23].
In our recently published papers, we have demonstrated that
repetitive application ofHBOT after cortical injury prevented
neurodegeneration due to the reduction of oxidative stress
[24] and improved neuroplastic responses, which contributed
to the recovery of motor performances and sensorimotor
integration in rats [25].
Although hyperbaric medicine is advancing, and under-
standing of its beneficial effects in many diseases has been
improved, the studies exploring possible anti-inflammatory
effects of HBO after stab brain injury are lacking. Therefore,
in this study we explored the potential of HBOT to reduce
astrocyte-mediated inflammatory response to brain injury.
Our results indicate that repetitive HBOT limits production
of inflammatory mediators (CD40, CD40L, and ICAM-1),
prevents astrocyte activation, and reduces glial scar forma-
tion.
2. Materials and Methods
2.1. Animals. Theexperiments were performed on adultmale
Wistar rats (10 weeks old). All experimental procedures
received prior approval from the Ethical Committee of the
School of Medicine, University of Belgrade (number 3027/2),
and were in compliance with the Directive 2010/63/EU on
the protection of animals used for experimental and other
scientific purposes. At each stage of the experiment, all
possible steps were taken tominimize animal suffering and to
reduce the number of animals used. At the beginning of the
experiments, there was no statistically significant difference
in animal’s body weight (250 ± 30 g), within the group as
well as between the groups. All animals were housed in
fours per cage (55 × 35 × 30 cm), under standard conditions
(23 ± 2∘C, 50–60% relative humidity, 12 h/12 h light/dark
cycle with lights on at 07:00, with free access to food and
water). The period of adaptation lasted for one week. After
the acclimatization period, a cohort of 72 animals was divided
into 6 experimental groups in a randomized fashion (𝑛 =
12 per group): control group (C), intact rats; control HBO
group (CHBO), intact rats subjected to the HBO protocol
for 10 consecutive days; sham group (S), the animals that
underwent surgical procedure without skull opening and
were sacrificed 10 days after injury (dpi); sham HBO group
(SHBO), the animals that underwent sham surgery and were
subjected to the HBO protocol for 10 consecutive days;
lesion group (L), the animals that passed cortical stab injury
(CSI) and were sacrificed at 10th dpi; and lesion HBO group
(LHBO), CSI rats subjected to the HBO protocol for 10
consecutive days.
2.2. Cortical Stab Injury (CSI). Before starting the surgical
procedure, rats were weighted and anesthetized with ether.
Preoperatively, after the onset of anesthesia, the rat’s scalps
were shaved and then they were placed in stereotaxic frame.
The head was incised using a sterile scalpel blade and the
bleeding was minimized using cotton swabs. Using a hand
held 1mm wide dental drill the skull was surgically exposed,
and stab injury to the left cortex was performed at the
following coordinates: 2mm posterior to the bregma and
2mm lateral from the midline and to a depth of 2mm into
the brain [26]. The incision was closed with sutures. All rats
survived the procedure of induction of brain injury. Rats from
the sham control groups underwent anesthesia and the same
surgical procedure except inflicting stab injury. Intact animals
were untreated age-matched controls. After the surgery, the
rats were kept at warm and left up to 2 hours to recover before
they were included in the hyperbaric oxygen protocol. All
animals survived surgical procedure and quickly recovered
after operation.
2.3. HBO Treatment (HBOT) Protocol. As described pre-
viously [25] the rats were placed into experimental HBO
chambers and exposed to 100% oxygen according to the
following protocol: 10 minutes of slow compression, 2.5
atmospheres absolute (ATA) for 60 minutes, and 10 minutes
of slow decompression, once a day during 10-day period.
Upon reaching the desired pressure, the flow of oxygen was
reduced to maintain constant pressure while allowing the
flow out of the chamber. This constant exchange accompa-
nied by a tray of calcium carbonate crystals was used to
reduce the accumulation of CO in the chamber environment.
This protocol corresponds to a standard hyperbaric oxygen
treatment that is routinely used in the clinical setting of
Center for Hyperbaric Medicine, Belgrade, Serbia [25, 27],
and is in a line with recommendations of The Committee
of the Undersea and Hyperbaric Medical Society that a
treatment pressure only from 2.4 to 3.0 ATA should be used
as appropriate [28], Each exposure was started at the same
hour to exclude any confounding issues associated with the
changes in biological rhythm. Body temperature was not
changed significantly after the HBOT.
2.4. Tissue Processing for Gene Expression Analyses. Four rats
of each group were taken for gene expression analyses. After
the end of treatment protocol (at 10th day after surgery)
animals were sacrificed by decapitation under deep ether
anesthesia. Immediately after decapitation, the brains were
quickly removed from the skull. As described in our recently
published paper [24], from injured (left) cortices 2mm
sections around the center of lesion were dissected on ice,
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rapidly frozen in liquid nitrogen, and stored at −80∘C until
further processing. The same piece of tissue was dissected
from the left cortices of sham and intact controls. Total
cellular RNA was isolated from the brain tissue using TRIzol
isolation method (Invitrogen Life Technologies, Carlsbad,
CA, USA) as per manufacturer’s direction. RNA purity
and concentration were insured by gel visualization and
spectrophotometrically by calculating the ration between the
absorbance at 260 nm and 280 nm. The absorbance ratio for
all samples ranged between 1.8 and 2.1. RNA was transcribed
to cDNA using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) according to manufacture instruc-
tions.
2.5. Real Time (RT)-PCR. TaqMan PCR reactions were per-
formed with Assay-on-Demand Gene Expression Products
(Applied Biosystems) for GFAP (Assay ID Rn00566603 m1)
and ICAM-1 (Assay ID Rn 00564227). PCR reactions were
carried out in the ABI Prism 7000 Sequence Detection
System at 50∘C for 2min, at 95∘C for 10min, followed
by 40 cycles, at 95∘C for 15 s, and at 60∘C for 1min. A
reference, endogenous control, was included in every
analysis to correct the differences in interassay amplification
efficiency, and the expression of each gene was normalized
to GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
expression. The obtained results were analyzed by RQ
Study Add ON software for 7000 v 1.1 SDS instrument
(ABI Prism Sequence Detection System) with a confidence
level of 95% (𝑃 < 0.05). The cDNA products were used
for quantitative real-time PCR carried out with the SYBR
Green PCRMaster Mix gene expression assay (Applied Bios-
ystems, UK) according to the manufacturer’s instructions.
Reactions were conducted in the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, USA). Relative
gene expression was calculated by comparing CT value of
the gene of interest to the CT value of GAPDH, internal
control (the 2-ΔΔCT method). The following primer pairs
from Invitrogen, Germany, were used: GAPDH (157 bp
product): forward, TGGACCTCATGGCCTACAT; reverse
GGATGGAATTGTGAGGGAGA; and vimentin (87 bp
product): forward CGTACGTCAGCAATATGAAAGTGTG;
reverse TCAGAGAGGTCAGCAAACTTGGA. GAPDH
and vimentin were amplified at an annealing temperature
of 60∘C for 40 cycles. The PCR products were run on 2%
agarose gels and visualized under UV light (data not shown).
2.6. Western Blot Analysis. After decapitation brains were
removed, left cortices were dissected and pooled from four
animals. The selected tissue was homogenized with a hand-
held pestle in sodium dodecyl sulfate (SDS) sample buffer
(10mL/mg tissue), which contained a cocktail of proteinase
and phosphatase inhibitors. The electrophoresis samples
were heated at 100∘C for 5min and loaded onto 10% SDS-
polyacrylamide gels with standard Laemmli solutions (Bio-
Rad Laboratories, CA, USA). The proteins were blotted onto
a polyvinylidene difluoridemembrane (PVDF, Immobilon-P,
Millipore, Billerica, MA, USA). The membranes were placed
in a blocking solution, which contained Tris-buffered saline
with 0.02% Tween (TBS-T) and 5% nonfat dry milk, for
1 h, and incubated overnight under gentle agitation with
primary antibody rabbit anti-GFAP (1 : 7000 Dako, Glostrup,
Denmark), mouse antivimentin (1 : 5000, Dako, Glostrup,
Denmark), goat anti-CD40L (1 : 1000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), and mouse anti-𝛽-actin (1 : 1000;
Sigma, St. Louis, MO, USA), respectively. Bound primary
antibodies were detected with a horseradish peroxidase-
(HRP-) conjugated anti-rabbit, anti-mouse, or anti-goat sec-
ondary antibody (1 : 5000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Between each step, the immunoblots were
rinsed with TBS-T. Immunoreactive bands were visualized
on X-ray films (Kodak) using chemiluminescence. Optical
densities of immunoreactive bands from 4 independent blots
were calculated in Image Quant program. The densities of
GFAP, vimentin, CD40L, and 𝛽-actin immunoreactive bands
were quantified with background subtraction. Squares of
identical sizes were drawn around each band to measure
density, and background near that band was subtracted. For
each blot, optical densities were normalized against 𝛽-actin
levels.
2.7. Tissue Processing for Immunohistochemical and Immuno-
fluorescence Analyses. For immunohistochemical and im-
munofluorescence analyses, brains (four per group) were
quickly removed and fixed in 4% paraformaldehyde in 0.1M
phosphate buffer (PBS), pH 7.4 for 12 hours at 4∘C. For
cryoprotection brain tissue was transferred into the graded
sucrose (10–30% in 0.1MPBS, pH7.4).The brainswere frozen
in 2-methylbutane and kept at −80∘C until sectioning on
cryotome. Coronal sections (25𝜇m thick) of the left cortex
were collected serially, mounted on superfrost glass slides,
dried for 2 h at room temperature, and stored at −20∘C until
staining. Immunohistochemical and immunofluorescence
data were determined on 5–7 slides per rat. No significant
differences in immunoreactivity between C, CHBO, S, and
SHBO controls were observed (data are shown as supple-
mented material in Supplementary Material available online
at http://dx.doi.org/10.1155/2015/498405).
2.8. Immunohistochemistry. Single labeling for GFAP, vimen-
tin, CD40, CD40L, and ICAM-1 was performed according
to the standard procedure. Briefly, after neutralization of
endogenous peroxidase with 0.3% H
2
O
2
in methanol for
20min at room temperature and washing in PBS, the sec-
tions were blocked by 5% normal donkey serum (Sigma,
Germany) in order to reduce non-specific binding. Sections
were incubated overnight at 4∘C with primary antibod-
ies: rabbit anti-GFAP (1 : 500; Dako, Glostrup, Denmark);
mouse anti-vimentin (1 : 500; Dako, Glostrup, Denmark);
rabbit anti-CD40, goat anti-CD40L; and goat anti-ICAM1
(1 : 100; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Using appropriate peroxidase linked secondary antibody
(1 : 200, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
the products of immunoreactions were visualized with 3󸀠3-
diaminobenzidine (DAB, Dako, Glostrup, Denmark) accord-
ing to manufacturer’s instructions. The specificity of the
stainingwas tested on the sections in the seconddish by omis-
sion of the primary specific antibodies. No immunoreactive
products were found on these sections. After dehydration
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and clearing, sections were mounted with DPX Mounting
medium (Fluka) and examined under Carl Zeiss Axiovert
microscope (Zeiss, Gottingen, Germany). In order to quan-
tify the reduction of glial scar size after HBOT we measured
GFAP/vimentin DAB staining intensity as described in [29].
Images were captured under the same conditions on a Zeiss
Axiovert (Zeiss, Jena, Germany). Then, image colors were
inverted in Photoshop 7.0 (Adobe Systems, San Jose, CA), and
luminosity of glial scar (histogram function in Photoshop)
was determined as mean intensity of five areas of a fixed size
(500×200 𝜇m) around the lesion site.The data were collected
from 3 consecutive brain slices per rat and four rats per group.
2.9. Immunofluorescence Analysis. Colocalization of ICAM-
1, CD40 and CD40L with specific markers of neuronal cell
bodies (neuronal specific nuclear protein, NeuN), dendrites
(Microtubule-associated protein 2, MAP-2),reactive astro-
cytes (GFAP), microglia (ionized calcium binding adapter
molecule 1, Iba1), and neutrophils (R-MC46) was exam-
ined with double immunofluorescence labeling. Cells nuclei
were stained with DAPI (diamidino-2-phenylindole). Anti-
gen retrieval step in the heated citrate buffer (pH 6) and
tissue permeabilization with 0.3% Triton X-100 in PBS were
performed in order to enhance the staining, where it was
necessary. Normal donkey serum (Sigma) was used for
blocking of unspecific labeling as 5% solution in PBS. For
immunofluorescent double-labeling, section was incubated
first with goat anti-ICAM-1 (1 : 100; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), goat anti-CD40L (1 : 100; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-
CD40 (1 : 100; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), followed by specific cell marker antibodies: rabbit anti-
GFAP (1 : 500; Dako, Glostrup, Denmark), mouse anti-NeuN
(1 : 200, Millipore, USA), mouse anti-MAP-2 (1 : 100; Sigma,
Germany), goat anti-Iba1 (1 : 400, Abcam, Cambridge, MA,
USA), or mouse anti-R-MC46 (1: 200, a kind gift of prof. Sasa
Vasilijic, Institute for Medical Research, Military Medical
Academy, Belgrade, Serbia).Mouse anti-R-MC46was used to
identify neutrophils [30]. Immune complexes were visualized
with donkey anti-goat Alexa Fluor 488 and donkey anti-
rabbit IgG Alexa Fluor 555 (1 : 250, Invitrogen, Carlsbad,
CA, USA) or with donkey anti-rabbit IgG Alexa Fluor 488
and donkey anti-mouse Alexa Fluor 555 (1 : 250, Invitrogen,
Carlsbad, CA, USA), while nuclei were counterstained with
DAPI (Invitrogen, Grand Island, NY, USA). Control sections
were also incubated with appropriated secondary antibodies
without the primary antibody as a negative control. The
sections were mounted in mowiol (Calbiochem, San Diego,
CA) and examined under the Carl Zeiss Axiovert fluores-
cent microscope (Zeiss, Gottingen, Germany) equipped with
camera and EC Plan-Apochromat 100x objective, using the
ApoTome software module for generating optical sections
through fluorescence samples. Images were acquired on
magnifications as indicated.
2.10. Statistical Analysis. All data were collected and analyzed
by researcher blinded to the surgery and HBOT protocol
used. Results were presented as mean ± SEM. Significance of
difference between the data obtained for different groups was
determined using Student’s t-test.The values of𝑃 ≤ 0.05were
considered statistically significant.
3. Results
It is important to note that there was no statistically sig-
nificant difference between data obtained for C, CHBO, S,
and SHBO groups and, therefore, for immunohistochemical
analysis all comparisons were done with respect to intact
controls (data are shown as supplemented material).
3.1. The Response of Astroglial Cells to HBOT following CSI.
To investigate the effect of repetitive HBOT on reactive
astrogliosis and glial scar formation after CSI we followed
expression of GFAP and vimentin (as markers of astrocytic
activation) at gene, protein, and tissue levels in the left
cortices.
3.1.1. HBOT Reduces Gene, Protein, and Tissue Expression of
GFAP after CSI. Real-time PCR analysis was used to evaluate
the effect of HBOT and CSI on GFAP gene expression. After
CSI, the mRNA level of GFAP was increased 4-fold (𝑃 <
0.005) in the injured cortex with respect to intact control
and sham-operated animals. In contrast, repetitive HBOT
induced downregulation of GFAPmRNA expression to levels
detected in control groups (Figure 1(a)).
To assess the pattern of GFAP protein expression fol-
lowing CSI and HBOT, cortices were isolated 10 days after
injury. Immunoblot analysis showed that GFAP was present
as a single band with a molecular mass of about 50 kDa
(Figure 1(b)). Statistically significant increase (𝑃 < 0.005)
in GFAP expression was detected after CSI with respect to
physiological control and sham-operated animals. However,
repetitive HBOT induced a statistically significant (𝑃 < 0.05)
decrease in GFAP expression.
Immunostaining with anti-GFAP antibody revealed a
paucity of fibrous astrocytes with small cell bodies and long,
thin processes throughout the cortex of intact rat (Figures
1(d) and 1(e)). CSI induced an increase of GFAP staining in
reactive astrocytes 10 days after injury (Figures 1(f) and 1(g)).
Noticed reactive astrocytes had pronounced hypertrophy of
cell body and processes (Figure 1(g) inset), with extension
of processes beyond the previous domains of individual
astrocytes. Hence, there is overlapping of astrocytic pro-
cesses without clear border between those processes. These
astrocytes form glial scar along the boundaries to necrotic
tissue (Figures 1(f) and 1(g)). After 10 successive HBOT glial
scar formation was significantly reduced (Figures 1(h) and
1(i)). The majority of astrocytes had fibrous morphology
(Figure 1(i) inset), similar to that observed in controls, and
there was no overlapping of processes between astrocytes
(Figures 1(h) and 1(i)). In order to quantify the reduction
of glial scar size after HBOT we measured GFAP staining
intensity around the lesion site. The luminosity of glial scar
is presented on histogram (Figure 1(c)). HBOT induced
statistically significant (20%, 𝑃 < 0.005) reduction of glial
scar.
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Figure 1: Effect of repetitive HBOT on GFAP expression after CSI. CSI provoked upregulation of GFAP expression both at mRNA (a) and
protein (b) levels in the injured cortex compared to intact control and sham-operated animals, while repetitive HBOT reduced levels of GFAP
mRNA to those detected in control groups. (a) Bars represent mean ± SEM of GFAP mRNA (relative to GAPDH). (b) Immunoblot analysis
showed that GFAP was present as a single band with a molecular mass of about 50 kDa. Bars represent mean ± SEM of GFAP protein content
(relative to 𝛽-actin). Samples are from 4 animals per each group. Dot line represents mean of GFAPmRNA or protein level ± SEM (gray area)
measured in control animals. Letters indicate significance levels (𝑃 < 0.005) between lesioned (L) and intact control group, L versus sham
control (S) group, and L compared to lesioned group subjected to the HBO protocol (LHBO). The groups not sharing a common letter are
statistically different. Level of significance was analyzed using Student’s 𝑡-test. (c)The luminosity of glial scar is obtained by measuring GFAP
staining intensity around the lesion site and presented on histogram. ((d) and (e)) Throughout the cortex of intact rats a small number of
fibrous GFAP+ astrocytes is seen. ((f) and (g)) At 10 days after injury a huge number of reactive astrocytes with pronounced hypertrophy of
cell body and processes ((g) inset) form glial scar around the lesion site. ((h) and (i)) Ten successive HBOT significantly reduced glial scar
formation, and the majority of astrocytes attained fibrous morphology ((i) inset). Rectangles indicate where the high magnification images
are taken from. Scale bar = 50 𝜇m.
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3.1.2. HBOT Downregulates Vimentin Gene, Protein, and Tis-
sue Expression after CSI. Similarly to GFAP, vimentinmRNA
was also upregulated (2-fold, 𝑃 < 0.005) in the injured
cortices 10 days after the CSI compared to the control groups.
After HBOT level of vimentin mRNA significantly (𝑃 <
0.005) dropped to the control values (Figure 2(a)).
Western blot analysis showed that vimentin was present
as a single band with a molecular mass of about 57 kDa
(Figure 2(b)). CSI induced statistically significant (𝑃 < 0.005)
increase in vimentin expression compared to physiological
control and sham-operated animals. However, after repet-
itive HBOT, a slight decrease in vimentin expression was
observed, but it was not statistically significant.
Weak vimentin immunoreactivity was seen throughout
the cortex of intact rat (Figures 2(d) and 2(e)). At the 10th
day after CSI vimentin staining was significantly increased
in close vicinity to the lesion site (Figures 1(f) and 1(g)) but
less than GFAP. The cell bodies of vimentin+ astrocytes were
enlarged with thickened processes, but without processes
overlapping (Figure 2(g)). Repetitive HBOT reduces the
number of reactive astrocytes to a narrow border around the
lesion site (Figure 2(h)). Moreover, those astrocytes mostly
had fibrous form (Figure 2(i)). However, quantification of
glial scar composed of vimentin+ astrocytes did not show
statistically significant reduction of glial scar after HBOT
(Figure 1(c)).
3.2. HBOT Prevents ICAM-1 Expression after CSI at Gene and
Tissue Levels. As shown in Figure 3(a) CSI induced 3.34-
fold (𝑃 < 0.005) increase of ICAM mRNA levels in the
injured cortex, compared to the control levels. Alternatively,
10 successive treatments with HBO significantly decreased
(2.85-fold, 𝑃 < 0.005) ICAM mRNA expression returning it
to control levels (Figure 3(a)).
Throughout the control cortex weak ICAM-1 immuno-
reactivity was mostly associated with blood vessels
(Figure 3(b)). After the CSI a robust ICAM-1 immuno-
reactivity occurred around the lesion site and in the nearby
vasculature (Figures 3(c), 3(d), and 3(d) inset). Interestingly,
heavy immunostaining of blood vessels was seen in the
contralateral cortex as well (Figures 3(e) and 3(e) inset). In
addition, dark neuron-like cells stained with anti-ICAM-1
were seen in both injured and contralateral cortexes (Figures
3(d) and 3(e)). In the proximity and within the lesion site
a huge number of neutrophils and activated microglia,
as well as astrocyte-like cells, were stained with ICAM-1
(Figures 3(c), 3(c), inset and 3(d)). On the other hand, after
repetitive HBOT, ICAM1 immunoreactivity was diminished
and localized only within the lesion site (Figures 3(f) and
3(g)). Blood vessels were faintly stained as in control cortical
sections (Figure 3(g)).
To confirm colocalization of ICAM-1 immunoreactivity
with different cell types double-immunofluorescence staining
was performed. As it is shown at Figure 4 astrocytes that
coexpress ICAM-1 (Figures 4(a) and 4(d), green) and GFAP
(Figures 4(b) and 4(e), red) were found around the blood
vessels (Figure 4(c)) and in close vicinity to the lesion site
(Figure 4(f), yellow). Colocalization of ICAM-1 (Figure 4(g),
green) and MAP-2 (Figure 4(h), red) was detected mostly on
neuronal cell bodies (Figure 4(i)). Interestingly, only activated
microglia clustered along the border to the lesion site and
within the lesion site coexpress ICAM-1 (Figures 4(j)–4(l)).
Similarly, only at the borders and within the lesion core
strong ICAM-1 (Figure 4(m), green) immunofluorescence
completely overlaps with R-MC46+ neutrophils (Figure 4(n),
red) resulting in yellow fluorescence (Figure 4(o)).
3.3. Repetitive HBOT Significantly Prevented Neuroinflamma-
tion in the Injured Cortex. To assess the effect of HBOT
on the spreading of neuroinflammation after CSI we per-
formed immunostaining using anti-CD40 and anti-CD40L
antibodies. Colocalization of CD40 and CD40L immunore-
activity with different cell types was visualized using double-
immunofluorescence staining.
3.3.1. HBOT Inhibits CD40 Expression after CSI. Immuno-
histochemical analysis revealed that CD40 immunoreactivity
is constitutively expressed on neuron-like cells. In the con-
trol sections, CD40 staining was widely spread throughout
the whole cortex, predominantly localized on neuronal cell
bodies (Figures 5(a) and 5(b)). After the CSI, strong CD40
immunoreactivity was accumulated within the lesion area
(Figure 5(c)). CD40-expressing nonneuronal cells (probably
activated microglia and neutrophils) were seen within the
necrotic area of the lesion (Figure 5(c), inset). In addition,
in the perilesioned cortex most of the CD40 immunore-
activity was found in dark-stained pyknotic neurons and
in transected axonal processes (Figure 5(d)). Numerous
nerve fiber varicosities with the characteristic appearance of
strings of pearls were also stained with anti-CD40 antibody
(Figure 5(d), arrow head). In contrast, after 10 days of
HBOT a significant reduction of CD40 immunoreactivity
was detected within the lesion site and in the injured cortex
(Figure 5(e)). Weak immunostaining was associated with
a small number of inflammatory infiltrates (microglia and
neutrophils) (Figure 5(e)), while staining of neuronal cells
was negligible (Figure 5(f)).
In order to confirm CD40 expression on neuronal cell
bodies and dendrites double-immunofluorescence staining
for CD40 (green fluorescence, Figure 6(a)) and MAP-2 (red
fluorescence, Figure 6(b)) was performed. Obtained data
revealed that CD40 fluorescence signal was mostly detected
on neuronal cell bodies (Figure 6(c), yellow fluorescence).
Double immunofluorescence of CD40 (green fluorescence,
Figure 6(d), andNeuN (red fluorescence, Figure 6(e)) showed
their colocalization both on neuronal cell bodies andmultiple
varicosities on axons (Figure 6(f)).
3.3.2. CSI-InducedOverexpression of CD40L Is Downregulated
after HBOT. To investigate the effect of HBOT on pattern
of CD40L protein expression, left cortices were isolated 10
days after injury. Immunoblot analysis showed that CD40L
was present as a single band with a molecular mass of about
36 kDa (Figure 7(a)). There was a significant (𝑃 < 0.005)
increase in CD40L expression following CSI (L group) with
respect to intact control (C) and sham-operated animals (S).
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Figure 2: Repetitive HBOT reduces gene and tissue expression of vimentin after CSI. Upregulation of vimentin expression both at mRNA
(a) and protein (b) levels is observed after CSI in the injured cortex compared to intact control and sham-operated animals. (a) Repetitive
HBOT reduced levels of vimentin mRNA to those detected in control groups. Bars represent mean ± SEM of vimentin mRNA (relative to
GAPDH). (b) Immunoblot analysis showed that vimentin was present as a single band with a molecular mass of about 57 kDa. HBOT slightly
but not statistically significantly decreased vimentin expression. Bars represent mean ± SEM of vimentin protein content (relative to 𝛽-actin).
Samples are from 4 animals per each group. Dot line represents mean of vimentin mRNA or protein level ± SEM (gray area) measured in
control animals. Letters indicate significance levels (𝑃 < 0.005) between lesioned (L) and intact control groups, L versus sham control (S)
group, and L compared to lesioned group subjected to the HBO protocol (LHBO). The groups not sharing a common letter are statistically
different. Level of significance was analyzed using Student’s 𝑡-test. (c)The luminosity of glial scar is obtained by measuring vimentin staining
intensity around the lesion site and presented on histogram. ((d) and (e)) Vimentin immunoreactivity was negligible in the cortex of intact
rats. ((f) and (g)) After CSI vimentin staining was significantly increased in the proximity to the lesion site. Vimentin+ astrocytes had enlarged
cell bodies with thick processes. ((h) and (i)) After HBOT reactive astrocytes surrounded the lesion site as a narrow line. Rectangles indicate
where the high magnification images are taken from. Scale bar = 50 𝜇m.
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Figure 3: Repetitive HBOT reduces gene and tissue expression of ICAM-1 after CSI. (a) Repetitive HBOT attenuated injury-induced
upregulation of ICAM-1mRNAexpression in the injured cortex. Bars representmean± SEMof ICAM-1mRNA (relative toGAPDH). Samples
are from 4 animals per each group. Dot line represents mean of ICAM-1 mRNA level ± SEM (gray area) measured in control animals. Letters
indicate significance levels (𝑃 < 0.005) between lesioned (L) and intact control groups, L versus sham control (S) group, and L compared to
lesioned group subjected to theHBOprotocol (LHBO).The groups not sharing a common letter are statistically different. Level of significance
was analyzed using Student’s 𝑡-test. (b) In the control cortex ICAM-1 localization is present on the blood vessels (asterisk). ((c) and (d)) An
increased ICAM-1 immunoreactivity is seen around the lesion site after the CSI. Heavy immunostaining of blood vessels is demonstrated
both in ipsilateral (asterisk (d) and (e) inset) and contralateral cortex (asterisk (e) and (e) inset). The arrow denotes dark neuron-like cells
in injured (d) and contralateral cortex (e). ICAM-1-positive neutrophils, microglia ((c), (c) inset), and astrocyte-like cells ((d), arrow head)
were confined to the lesion area. (f) and (g) Repetitive HBOT reduced ICAM-1 immunoreactivity, while blood vessels were faintly stained
((g) asterisk). Rectangles indicate where the high magnification images are taken from. Scale bar = 50 𝜇m.
Compared to L group in LHBO group statistically significant
reduction (𝑃 < 0.005) of CD40L protein expression was
observed (Figure 7(a)).
CD40L immunoreactivity was found in blood vessels
throughout the whole cortex of control rats (Figures 7(b)
and 7(c)). After the CSI, an intense CD40L immunoreac-
tivity occurred in perilesioned area (Figure 7(d)), mostly in
hypertrophied astrocytes (Figure 7(e)) and in microglia and
neutrophils within the lesion site (Figure 7(d)). Interestingly,
some of CD40L-positive hypertrophied astrocytes were in
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Figure 4: ICAM-1 (green fluorescence) colocalization with different cell types around and within the lesion site. ICAM-1 ((a) and (d)) and
GFAP ((b) and (e) red fluorescence) coexpression was found in reactive astrocytes around the blood vessels ((c), arrow head) and in close
vicinity to the lesion site (f). Colocalization of ICAM-1 (g) andMAP-2 ((h) red fluorescence) was detected mostly on neuronal cell bodies (i).
ICAM-1 (j) colocalized only with activated microglia (Iba1, red fluorescence, (k)) clustered along the border to the lesion site and within the
lesion site ((l) yellow fluorescence). Also, ICAM-1 completely overlaps with R-MC46+ neutrophils ((n) red fluorescence) only at the borders
and within the lesion core ((o) yellow fluorescence)). Scale bar = 5 𝜇m.
close contact with endothelial cells via astrocytic end-feet
(Figure 7(e)). Repetitive HBOT decreased CD40L immunos-
taining in the injured cortex (Figures 7(f) and 7(g)). CD40L-
immunoreactive astrocytes acquired more resting, fibrous
form with small cell bodies, and thin, branched processes
(Figure 7(g)).
In order to better characterize astrocytic expression
of CD40L after CSI and HBOT we performed double-
immunofluorescence staining (Figure 8).TheCD40L-labeled
astrocytes were identified with the antibody against CD40L
(green fluorescence) and the astrocytic marker GFAP (red
fluorescence). No apparent differences in the pattern of
CD40L/GFAP immunostaining between all controls (C,
CHBO, S, and SHBO) were noted (data shown as sup-
plemented material). Populations of CD40L/GFAP positive
fibrous astrocytes with small cell bodies and thin pro-
cesses were scattered throughout the cortex of control rats
(Figure 8(c)). After the injury, strong CD40L immunoreac-
tivity occurred in GFAP+ astrocytes clustered around the
lesion site forming dense mesh of glial scar composed of
tightly interweaved cell processes. CD40L immunofluores-
cence completely overlaps with GFAP resulting in yellow
fluorescence (Figure 8(f)). This strong CD40L and GFAP
immunoreactivity occurred in the hypertrophied cell body, as
well as in the thick proximal and distal processes (Figure 8(i)).
After repetitive HBOT, reactive phenotype of astrocytes is
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Figure 5: Repetitive HBOT affects CD40 expression after CSI. ((a) and (b)) In control cortical sections CD40 is expressed on neuron-
like cells. (c) CSI increased CD40 immunoreactivity in the perilesioned cortex. ((c) inset) High magnification photomicrograph depicts a
typical neutrophil with round morphology and multiple nuclei (left up corner of inset), while the enlarged cell in the right corner of inset is
probably activated microglia. (d) CD40-positive dark-stained pyknotic neurons, transected axonal processes (denoted with arrows), nerve
fiber varicosities (arrow head), and blood vessels (asterisk) were abundantly present in perilesioned area. ((e) and (f)) 10 days of HBOT
significantly reduced CD40 immunoreactivity in the injured cortex. Rectangles indicate where the high magnification images are taken from.
Scale bar = 50 𝜇m.
CD40
(a)
MAP2
(b)
CD40/MAP2
(c)
CD40
(d)
NeuN
(e)
CD40/NeuN
(f)
Figure 6: CD-40 (green fluorescence) colocalization with markers of neuronal cells in the injured cortex. ((a)–(c)) Double-
immunofluorescence analysis of CD40 (a) and MAP-2 ((b) red fluorescence) revealed that CD40 fluorescence signal was mostly detected
on neuronal cell bodies ((c) yellow fluorescence). ((d)–(f)) CD40 (d) and NeuN ((e) red fluorescence) fluorescence colocalized not only on
neuronal cell bodies but also on axons (f). Arrow head points to varicosities along axons. Scale bar = 5𝜇m.
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Figure 7: Repetitive HBOT downregulates CD40L expression after CSI. (a) Immunoblot analysis showed that CD40L was present as a
single band with a molecular mass of about 36 kDa. After CSI expression of CD40L significantly (𝑃 < 0.005) increased in respect to intact
control (C) and sham-operated animals (S). However, compared to L group in LHBO group statistically significant reduction (𝑃 < 0.005)
of CD40L protein expression was observed. Bars represent mean ± SEM of CD40L protein content (relative to 𝛽-actin). Samples are from
4 animals per each group. Dot line represents mean of CD40L mRNA or protein level ± SEM (gray area) measured in control animals.
Letters indicate significance levels (𝑃 < 0.005) between lesioned (L) and intact control groups, L versus sham control (S) group, and L
compared to lesioned group subjected to the HBO protocol (LHBO).The groups not sharing a common letter are statistically different. Level
of significance was analyzed using Student’s 𝑡-test. ((b) and (c)) In control cortex CD40L was localized in blood vessels ((c) asterisk). (d) At
10th day after CSI intense CD40L immunoreactivity occurred in perilesioned area: ((d), inset) inmacrophages/microglia and neutrophils and
(e) in protoplasmic astrocytes in close contact with endothelial cells via astrocytic end-feet (asterisk). (f) Repetitive HBOT decreased CD40L
immunostaining in the injured cortex. (g) CD40L-positive astrocytes had fibrous form. Rectangles indicate where the high magnification
images are taken from. Scale bar = 50𝜇m.
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Figure 8: Double-immunofluorescence analysis of CD40L (green) and GFAP (red) colocalization after CSI and HBOT. ((a)–(c)) Sparse
CD40L/GFAPpositive fibrous astrocyteswere seen in the cortex of control rats. ((d)–(f)) StrongCD40L immunoreactivity occurred inGFAP+
astrocytes that form densemesh of glial scar in the area adjacent to the lesion site, providing an overlapping signal (yellow fluorescence). ((g)–
(i)) CD40L and GFAP signal is abundantly present at protoplasmic astrocyte cell bodies, and thick proximal and distal processes. ((j)–(l))
Repetitive HBOT decreased intensity of CD40L/GFAP immunofluorescence. ((m)–(o)) Reactive phenotype of astrocytes is transformed into
more resting form with smaller cell body and long processes resembling morphology of astrocytes from the control group. Scale bar = 50𝜇m.
changed into resting form with smaller cell body and long
processes. CD40L is expressed only in subpopulation of
fibrous astrocytes around the lesion site (Figures 8(j)–8(l)).
The morphology of these astrocytes was similar to astrocytes
from control group (Figures 8(m)–8(o)).
4. Discussion
Even though HBOT is in use for over the 50 years as a
primary or adjunctive therapy, both in experimental and
clinical studies, the underlying cellular and molecular mech-
anisms of hyperbaric oxygenation are still not fully iden-
tified [17, 18, 23, 31, 32]. Therefore, in this study we wanted
to explore its potential role in suppressing glia-mediated
neuroinflammatory response to brain injury. On the basis
of obtained data it is evident that repetitive HBOT applied
after the cortical injury (1) attenuates reactive astrogliosis
and reduces glial scarring, (2) reduces expression of GFAP,
vimentin, and ICAM-1 both at gene and tissue levels, and (3)
prevents expression of ICAM-1, CD40, and its cognate lig-
and CD40L on macrophages/microglia, neutrophils, cortical
neurons, and reactive astrocytes.
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The main concern in HBO therapy is oxygen toxicity
that can affect multiple organs, which depends on treatment
parameters: pressure and duration of the treatment [17, 33,
34]. In agreement with this knowledge, and according to
recommendations of the Committee of the Undersea and
HyperbaricMedical Society [28] and our previous experience
[25, 27], we exposed rats to 100% oxygen for 1 h at 2.5
atmospheres absolute for 10 consecutive days. Treatment
protocol with 10 exposures to hyperbaric oxygen has been
shown to have beneficial effects on improvement in learning
and memory in rats with vascular dementia [35]. Using such
HBOTprotocol, we avoid the potential risk of oxygen toxicity
and prevent the appearance of convulsions [36, 37].
4.1. RepetitiveHBOTAttenuates ReactiveAstrogliosis andGlial
Scar Formation after CSI. The stab wound injury, applied in
this study, creates a discrete and restricted trauma with a
necrotic area in the centre of thewound and reactive glial cells
bordering the area and is commonly used model for studying
the glial response following injury [38]. It is becoming
increasingly clear that these reactive glial cells, particularly
astrocytes, contribute both to the evolving of tissue damage
and to repair of the injured areas [39–41]. After the injury
astrocytes become rapidly activated during the process of
“reactive astrogliosis” and exhibit phenotypic heterogeneity
in molecular expression, morphology, and proliferation, in a
manner that is graded with respect to distance from acute
focal tissue lesions resulting from traumatic, ischemic, or
autoimmune injury [42]. Accordingly, in presented model of
cortical stab injury we have demonstrated robust activation
and proliferation of astrocytes in the perilesioned cortex.
These astrocytes exert pronounced hypertrophy of cell bodies
and processes that intertwine and intermingle extensively
and form a dense, fibrous glial scar along the boundaries of
lesion site. In addition, we have shown that these reactive
astrocytes upregulate gene and protein expression of GFAP
and vimentin, two intermediate filaments which are promi-
nent cellular hallmarks of reactive gliosis [41]. Repetitive
HBOTmarkedly reducedGFAP and vimentinmRNAexpres-
sion, almost to the physiological level. At the protein level,
HBOT induced statistically significant reduction of GFAP
expression, as well. HBOT-induced phenotypic changes of
GFAP+ and vimentin+ astrocytes were maximal adjacent to
the damaged tissue, where the majority of reactive astrocytes
showed reduced hypertrophy of cell body and had elongated,
thin processes that overlap far less extensively or remain
within their original territories. Additionally, quantification
of luminosity of glial scar composed of GFAP+ astrocytes
around the lesion site revealed statistically significant reduc-
tion of glial scar after HBOT. HBO-induced suppression of
microgliosis and astrogliosis was reported to contribute to
beneficial effects of HBO treatment in cerebral ischemia [43],
neuropathic, and inflammatory pain [44, 45]. Interestingly,
Lee et al. [46] reported that prolonged HBOT (for 3 weeks)
may increase degree of gliosis indicating that longer oxygen
cycling might help in overcoming detrimental effects of
gliosis and providing its beneficial effects.
4.2. Repetitive HBOT Prevents Spreading of the Neuroinflam-
mation after CSI. The accumulation of neutrophil granulo-
cytes around the site of injury and their infiltration into the
injured brain area is crucial for the initiation and progression
of inflammation and the extent of secondary brain damage
[16, 47]. In our study we have also noted a huge number
of neutrophils and activated microglia closely compacted
into the lesion core and clustered along the border to the
lesion site. ICAM-1 belongs to immunoglobulin superfamily
and is critical for the firm arrest and transmigration of
leukocytes out of blood vessels and into tissues. Its consti-
tutive expression is documented on endothelial cells and is
increased by proinflammatory cytokines [48]. In the present
study, we have demonstrated that cortical injury induces
upregulation of ICAM-1 mRNA expression. Similar signifi-
cant and extended induction of ICAM-1 mRNA expression
was demonstrated after penetrating ballistic-like brain injury
[49] and in the model of focal ischemia [50]. Upregulation
of ICAM-1 in cerebral microvessels has been described in
several brain pathologies, including brain trauma [50–52].
In our study increased ICAM-1 immunostaining of blood
vessels was seen not only in the injured cortex but also
on the vessels in contralateral, noninjured cortex pointing
to transhemispheric diaschisis, which is usually regarded as
functional changes caused by the interruption of input from
the lesioned brain region [53]. Our results are in accordance
with data obtained by other authors who noticed persistent
upregulation of ICAM-1 in contralateral hemisphere as well
[50–52, 54]. Further, we have noticed increased ICAM-
1 immunoreactivity in a few dark, pyknotic neurons with
shrunken neuronal somata, which is consistent with findings
of other authors who also found upregulation of ICAM-1 in
degenerating neurons [51, 55–57]. One potential explanation
for neuronal expression of ICAM-1 is that attachment of
leukocytes and/or microglia to healthy neurons could induce
neuron injury, either through direct cell-to-cell interaction or
by release of potentially cytotoxic substances [51, 56]. More
likely, it is suggested that expression of ICAM-1 on degen-
erating neurons may act as intercellular recognition signal
which facilitates their elimination by phagocytotic microglia,
neutrophils, natural killer cells, monocytes, and cytotoxic T
cells [51, 55, 57]. Therefore, therapeutic interventions aimed
on reducing ICAM-1 expression and targeting the passage
of immune cells through the BBB via inhibition of cell
adhesion molecules present an interesting avenue to dampen
the neuroinflammatory response to TBI. Herein, we have
demonstrated that HBOT has potential of reducing ICAM-
1 expression after CSI both on gene and tissue levels. Thus,
injury-induced upregulation of ICAM-1 mRNA expression
declined to the control levels following the HBOT. In addi-
tion, after HBOT no ICAM-1 immunoreactivity was detected
on blood vessels in the injured cortex, while faintly stained
ICAM-1 positive neutrophils were spread through lesion
core. Several studies have also shown that HBOT reduced
the expression of ICAM-1 and adhesion of neutrophils to
the endothelium which correlated with improved neurologic
outcome [21, 58–61].
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CD40/CD40L interaction stimulates the endothelial cells
to upregulate the expression of adhesionmolecules, including
ICAM-1, which then enhances adhesion and the subsequent
transmigration of inflammatory cells across the BBB to the
sites of inflammation in the CNS, suggesting an important
role for the CD40/CD40L dyad in regulating BBB functions
[6, 62]. Indeed, CD40 or CD40L deletion has been shown
to diminish the ICAM-1 expression on endothelial cells and
prevent neurodegeneration [63]. Having all this in mind we
further investigate the influence of CSI and HBOT on CD40
andCD40L expression and cellular localization in the injured
cortex.
CD40 is a membrane protein that belongs to the tumor
necrosis factor (TNF) receptor family and is expressed on
a variety of immune and nonimmune cells, suggesting that
CD40 plays a much broader role in cellular processes than
it was primarily suspected [6, 64]. In control animals we
have detected CD40 immunoreactivity throughout the whole
cortex, predominantly localized on neuronal cell bodies.
Constitutive expression of CD40 by cortical neurons and
primary cultured neuronal and neuron-like cells is also
reported by Tan et al. [65]. However, after the CSI we have
detected strong CD40 immunoreactivity within the lesion
area on nonneuronal cells (most likely activated microglia
and neutrophils) and vascular endothelium. Our results are
consistent with findings which demonstrated remarkable
enhancement of CD40 expression by multiple cell types in
theCNS, including tissuemacrophages,microglia, astrocytes,
vascular endothelial, and smooth muscle cells and neurons,
indicating a role of CD40 in neuroinflammation [7, 62,
63, 65, 66]. Additionally, we have found that most of the
CD40 immunoreactivity in the perilesioned cortex was asso-
ciated with dark-stained pyknotic neurons and transected
axonal processes. Double-immunofluorescence staining with
CD40 and MAP-2 revealed CD40 expression on neuronal
cell bodies and axons. In addition, as shown by double-
immunofluorescence staining for CD40 and NeuN, multiple
nerve fiber varicosities were also stained with anti-CD40
antibody suggesting its role in promoting neurodegeneration.
Involvement of CD40 in activation of pathogenic cascade that
will result in neuronal cell death is documented in awide vari-
ety of neuroinflammatory and neurodegenerative diseases
[57, 63, 64, 67]. In the present study we used hyperbaric
oxygenation to prevent these CD40-induced pathological
processes after brain injury. Indeed, obtained data revealed a
significant reduction of CD40 expression in the perilesioned
cortex after repetitive HBOT.
CD40 explore its full activation after ligation with its
natural ligand, CD40L, which has a broad spectrum of
functions [68]. It is suggested that reactive astrocytes are a
predominant source of CD40L in the brain [6, 9]. Immuno-
histochemical data of the current study revealed the presence
of very low, constitutive levels of CD40L immunoreactivity
in blood vessels, while no CD40L staining occurred in
astrocytes in the cortex of intact brain. Stab injury to the
brain produced an induction of CD40L protein expres-
sion and increased CD40L immunoreactivity in hypertro-
phied astrocytes throughout the injured cortex, which often
were in close association with intensively stained vascular
endothelium forming so called “perivascular” end-feet. In
addition, CD40L-positive macrophages/microglia and neu-
trophils were seen within the lesion area. Using double-
immunofluorescence CD40L/GFAP staining we detected a
strong CD40L immunoreactivity in GFAP+ astrocytes clus-
tered around the lesion site which occurred in the hypertro-
phied cell bodies, as well as in the proximal and distal pro-
cesses. Our results are consistent with findings of Calingasan
et al. [9] who have shown intense CD40L expression in a
subset of GFAP-positive astrocytes around the lesion site in
the same model of CSI. Considering the ability of CD40L
to trigger an inflammatory reaction of vascular endothelial
cells [69] the same authors [9] proposed that CD40L from
astrocytesmay synergizewith the enhancedCD40 expression
to trigger an inflammatory reaction of endothelial cells.
Thus, CD40/CD40L interaction by astrocytes could initiate
multiple signaling cascades that lead to the release of key
proinflammatory mediators. Importantly, we have found
that application of ten successive HBOT markedly reduced
CD40L expression in the perilesioned cortex, while CD40L-
immunoreactive astrocytes acquired more resting, fibrous
form similar to those from control group.
5. Conclusion
In summary, this study reveals for the first time that repetitive
HBOT attenuates reactive astrogliosis, suppresses formation
of glial scar, and prevents activation of CD40/CD40L/ICAM-
1 deleterious cascade of events after cortical stab injury.
Moreover, HBOT effectively decreased glia-mediated inflam-
matory response and tissue-damaging effects of neutrophils
and prevented neuronal degeneration after CSI. Considering
CD40/CD40L and ICAM-1 involvement in amplification of
immune response after brain injury, observed reduction of
their expression after HBOT confirmed the role of HBOT
in attenuation of inflammatory responses after TBI. Thus,
HBOT, by limiting production of inflammatory mediators
fosters formation of more permissive environment for repair
and regeneration.
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